Apollo Tyres acquires Germany Reifencom

After having failed to acquire the US based Cooper Tire in a $2.5 Billion deal, the country second largest tyre manufacturer by Sales, Apollo Tyres had acquired Reifencom GmBH, one of the largest tyre distributors in Germany for Euro 45.6 Million.

Reifencom GmBH has an online presence in six countries – Germany, France, Italy, Austria, Switzerland, and Denmark. In Addition, it operates 37 stores and service centres across Germany. Acquisition will enable Apollo to improve its mix of distribution channels in Germany and Europe and aid in increasing the visibility of Apollo and Vredestein tyres offline and especially in the fast growing online retail space.

Reifencom has turnover of 147 Million euro in 2014. The acquisition will give Apollo two benefits: increase in number of channels overseas as well as access to retailing multiple brands. Apollo already has 3,500 dealers/partners in Europe which will now get further enhanced due to the acquisition of Reifencom.

The success of Reifencom GmBH is attributed to its highly efficient logistics system, which ensures there is a guarantee of a high degree of availability of all kinds of tyres and rims, even during busy periods like spring and autumn. Reifencom GmBH procures tyres and rims from leading manufacturers thereby ensuring a high level of quality.

Mylan acquired Famy Care Business

Mylan Inc. is a global generic and specialty pharmaceuticals company headquartered in Pennsylvania. In 2007, Mylan acquired a controlling interest in India based Matrix Laboratories Limited, a top producer of generic drugs, and the generic business of Germany based Merck KGaA. Through these acquisitions, Mylan has grown from the third largest generic company in United States to the second largest generic and Pharmaceuticals Company in the world.

Recently, Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement to acquire certain female health care businesses from Famy Care Limited, a specialty women’s health care company with global leadership in generic oral contraceptive products for $750 Million in cash plus additional contingent payments of up to $50 Million. The acquisition will build on Mylan existing partnerships with Famy care in North America, Europe, and Australia.

Famy Care, headquartered in Mumbai, India, offers a comprehensive range of women’s health products including oral and injectable contraceptives, intra-uterine devices (IUDs), tubal rings, and hormone replacement therapy products. More than 15% of the world women using oral contraceptive pills today use a Famy Care product. It is the world largest producer of generic OCPs, with four high quality-manufacturing facilities in India, two of which have been approved by U.S. Food and Drug Administration (FDA) and the European Union.

Famy Care is the first generics company to have received prequalification from the WHO for hormonal contraceptives. This manufacturing base represents one of the lowest cost and largest dedicated to OCPs globally, and brings Mylan Strong capabilities in OCP cycles, injectable, IUDs, and tubal rings. Famy Care has a strong presence in the private, institutional, and non-governmental organization sectors and markets its products in more than 90 countries around the world.